{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:48:32Z","timestamp":1768078112819,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172272, 81871697"],"award-info":[{"award-number":["82172272, 81871697"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2023.1060481","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T04:50:31Z","timestamp":1679287831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Lessons from Pasteur may help prevent the deadly relapse of Ebola in patients: Using contingency vaccination to avoid Ebola relapse in immune-privileged organs"],"prefix":"10.3389","volume":"14","author":[{"given":"Wei","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuantao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingfeng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: A case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.02.006","article-title":"Ebola Virus persistence as a new focus in clinical research","volume":"23","author":"Caviness","year":"2017","journal-title":"Curr Opin Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500306","article-title":"Persistence of Ebola virus in ocular fluid during convalescence","volume":"372","author":"Varkey","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268816000054","article-title":"Persistence of Ebola virus in various body fluids during convalescence: Evidence and implications for disease transmission and control","volume":"144","author":"Chughtai","year":"2016","journal-title":"Epidemiol infection"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi5229","article-title":"Ebola Virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors","volume":"14","author":"Liu","year":"2022","journal-title":"Sci Trans Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024670","article-title":"Ebola Virus transmission initiated by relapse of systemic Ebola virus disease","volume":"384","author":"Mbala-Kingebeni","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92335-3","article-title":"Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome","volume":"2","author":"Maiztegui","year":"1979","journal-title":"Lancet"},{"key":"B8","article-title":"Protection of monkeys against machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin)","volume":"52","author":"Eddy","year":"1975","journal-title":"Bull World Health Organ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/S0140-6736(22)02573-9","article-title":"Pasteur\u2019s legacy in 21st century medicine","volume":"400","author":"The","year":"2022","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1601030","article-title":"Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice","volume":"8","author":"Scholte","year":"2019","journal-title":"Emerging Microbes Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.110","article-title":"Hepatitis b vaccines: WHO position paper\u2013recommendations","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00361-w","article-title":"Viral hepatitis and pregnancy","volume":"18","author":"Terrault","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001791","article-title":"Elimination of hepatitis b virus infection in children: experience and challenge in China","volume":"134","author":"Tang","year":"2021","journal-title":"Chin Med J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca suffit)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/1871526519666181123145540","article-title":"Insights into Ebola virus VP35 and VP24 interferon inhibitory functions and their initial exploitation as drug targets","volume":"19","author":"Fanunza","year":"2019","journal-title":"Infect Disord Drug Targets"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1165","article-title":"Postexposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the united kingdom: An operational, safety, and immunogenicity report","volume":"71","author":"Davis","year":"2020","journal-title":"Clin Infect diseases: an Off Publ Infect Dis Soc America"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1995","article-title":"Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick","volume":"313","author":"Lai","year":"2015","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy698","article-title":"PREVAIL I cluster vaccination study with rVSV\u0394G-ZEBOV-GP as part of a public health response in Liberia","volume":"219","author":"Bolay","year":"2019","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): An open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1060481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T04:50:34Z","timestamp":1679287834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1060481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2023.1060481"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1060481","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"article-number":"1060481"}}